Detalhe da pesquisa
1.
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.
Breast Cancer Res Treat
; 138(1): 149-55, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23378064
2.
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Cancer Res
; 83(23): 3989-4004, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37725704
3.
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
Breast Cancer Res Treat
; 136(2): 503-11, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23065000
4.
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
NPJ Breast Cancer
; 7(1): 44, 2021 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33863913
5.
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
Breast Cancer Res Treat
; 123(2): 453-61, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20632084
6.
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Clin Cancer Res
; 26(15): 3947-3957, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32312891
7.
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.
Clin Cancer Res
; 26(16): 4242-4249, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32234755
8.
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Clin Cancer Res
; 26(7): 1574-1585, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31836609
9.
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Cancer Discov
; 10(10): 1528-1543, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32532747
10.
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer.
Clin Cancer Res
; 24(15): 3510-3518, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29440181
11.
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Clin Cancer Res
; 24(9): 2050-2059, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29066505
12.
Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.
PLoS One
; 12(5): e0175779, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28472036
13.
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Clin Cancer Res
; 28(24): 5469, 2022 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36519303
14.
AKT Inhibition in Solid Tumors With AKT1 Mutations.
J Clin Oncol
; 35(20): 2251-2259, 2017 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28489509
15.
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
J Clin Oncol
; 30(16): 1919-25, 2012 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22370325
16.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
J Clin Oncol
; 28(30): 4594-600, 2010 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20855825